Back HIV/HCV Coinfection

HIV/HCV Coinfection

Pharmasset Starts Phase 3 Trials of PSI-7977 Without Interferon

Pharmasset, Inc. announced this week that it has begun a Phase 3 program of studies of its hepatitis C virus (HCV) polymerase inhibitor PSI-7977 taken once-daily in combination with ribavirin but not pegylated interferon. These trials will enroll previously untreated people with HCV genotype 2 or 3, and patients with any genotype who cannot use interferon.alt

Read more:

EACS 2011: Predictors of HCV Viral Load in HIV/HCV Coinfected Patients

Hepatitis C virus (HCV) RNA levels rise over time in HIV/HCV coinfected people, reducing the chances of sustained response to interferon-based treatment. But antiretroviral therapy may help control HCV viral load and contribute to higher likelihood of treatment success, according to a report presented at the 13th European AIDS Conference (EACS 2011) this month in Belgrade.alt

Read more:

IAS 2011: Transplants Safe for HIV+ People but HCV Adds Risk

Kidney and Liver transplants can be safe and effective for people living with HIV. However hepatitis C virus (HCV) coinfection and several other factors may make such procedures more risky. alt

Read more:

IDSA 2011: Boceprevir Increases Hepatitis C Treatment Response for HIV/HCV Coinfected People

The recently approved hepatitis C virus (HCV) protease inhibitor boceprevir (Victrelis) added to pegylated interferon/ribavirin significantly improved the likelihood of virological response at week 24 in HIV/HCV coinfected patients, according to a late-breaker presentation at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA 2011) in Boston.alt

Read more:

Gene Patterns Predict Fibrosis in HIV/HCV Coinfected People

Certain haplogroups, or gene pattern clusters, were associated with reduced risk of liver fibrosis among European patients with HIV and hepatitis C coinfection.

Read more:

EACS 2011: Antiretroviral Therapy Reduces Liver Fibrosis Progression in HIV/HCV Coinfected People

Earlier initiation of antiretroviral therapy (ART) and spending more time on HIV treatment may help slow liver disease progression in HIV/HCV coinfected patients, according to an Italian study using non-invasive methods presented at the 13th European AIDS Conference (EACS 2011) last week in Belgrade.alt

Read more:

HIV/HCV Coinfected Have Stronger CD8 T-cell Response to HCV

HIV positive people coinfected with hepatitis C virus (HCV) demonstrated stronger CD8 T-cell responses against HCV, which may contribute to accelerated liver disease progression.

Read more:

ICAAC 2011: Interferon May Reduce Liver Disease Progression in HIV/HCV Coinfected Relapsers

Unsuccessful interferon-based therapy for chronic hepatitis C virus (HCV) infection appeared to improve or slow liver fibrosis progression in HIV/HCV coinfected people, but this was usually temporary, according to 2 studies presented the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) last month in Chicago.

Read more:

Viral Load, HIV Status, but not IL28B Predict Perinatal HCV Transmission

Women with higher HCV viral load and those coinfected with HIV were more likely to transmit HCV to their babies in a recent Spanish study. IL28B gene pattern did not affect transmission directly, but babies with the favorable CC pattern more often spontaneously cleared HCV.

Read more:

ICAAC 2011: Maraviroc May Reduce Liver Fibrosis in HIV/HCV Coinfected People

Adding the CCR5 blocker maraviroc (Selzentry) to an antiretroviral regimen reduced liver stiffness, an indicator of fibrosis, according to a study presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) this week in Chicago.

Read more:

Treatment Interruption Spurs Fibrosis in HIV/HCV Coinfected People

Stopping antiretroviral therapy led to liver fibrosis progression in HIV/HCV coinfected people, an effect that was not fully attributable to increased HIV viral load or reduced CD4 cell count.

Read more:

ICAAC 2011: Didanosine, Higher HCV Viral Load Predict Liver Fibrosis in HIV/HCV Coinfected People

Use of didanosine (ddI, Videx) -- along with higher hepatitis C virus (HCV) RNA level, male sex, and older age -- was a significant risk factor for liver fibrosis in people with HIV/HCV coinfection, researchers reported at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) this week in Chicago.alt

Read more:

EASL 2011: HIV/HCV Coinfection among HIV Positive Gay Men

Researchers at EASL presented further data on outbreaks of sexually transmitted HCV among HIV positive men who have sex with men. Sustained response rates are high when interferon-based therapy is started during acute infection, but re-infection after treatment is common in this population. alt

Read more:

Hepatitis B and C Coinfection among HIV Positive People in the U.S.

Liver disease and coinfection with hepatitis B or C are common among people with HIV, according to a recent analysis, leading researchers to recommend that viral hepatitis screening, vaccination, and treatment should be considered a priority for HIV positive individuals.alt

Read more:

EASL 2011: Liver Disease Progression in HIV/HCV Coinfected People

Liver stiffness measured by FibroScan is a good predictor of liver cancer, end-stage liver disease or death among people with HIV/HCV coinfection, researchers reported as EASL 2011.

Read more:

Alarming Rate of Hepatitis C Re-infection among HIV+ Gay Men

One-third of HIV positive men who have sex with men (MSM) who were treated for acute hepatitis C virus (HCV) infection in Amsterdam became re-infected within 2 years, indicating a need for improved prevention efforts, according to a recent report.alt

Read more:

CROI 2011: HIV/HCV Coinfected People Have Higher Risk of Bone Loss

People with both HIV and hepatitis C are more likely to sustain hip or spine fractures than people with one or none of these viruses, according to a study of nearly 39,000 Medicaid recipients presented at CROI 2011. alt

Read more:

Treatment of HIV/HCV Coinfected People with Compensated Liver Cirrhosis

HIV positive people with compensated liver cirrhosis related to chronic hepatitis C virus (HCV) responded as well to treatment with pegylated interferon and ribavirin as coinfected patients without cirrhosis, but they should receive closer monitoring and may need more intensive management of side effects. alt

Read more:

CROI 2011: Interactions of HIV Meds with HCV drugs Telaprevir and Boceprevir

New HCV antiviral drugs can interact with some antiretroviral drugs for HIV, but others are not affected and HIV/HCV coinfected patients can be treated successfully with minimal dose adjustments.alt

Read more:

IAS 2011: Maraviroc Improves Liver Fibrosis in HIV/Hepatitis C Coinfected Patients

Treatment with maraviroc is associated with the regression of liver fibrosis in HIV-positive patients co-infected with hepatitis C, a small randomised study presented to the Sixth International AIDS Society conference (IAS 2011) in Rome shows.alt

Read more:

CROI 2011: Acute Hepatitis C Treatment for HIV/HCV Coinfected People

About 65% of coinfected patients with HCV genotypes 1 or 4, and 81% with genotypes 2 or 3, achieved sustained response to interferon-based therapy started during acute infection, researchers reported at CROI 2011.

Read more: